TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Apparent terminal half-life (t1/2) of CYP450 substrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in central arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Prostate Specific Antigen (PSA) failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall perceived stress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complete Response (CR) / Complete Response With Partial Hematologic Recovery (CRh) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Evaluation and treatment effectiveness of pancreatobiliary disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Detection rate of lung nodule
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of inflammatory and non-inflammatory acne lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants With Confirmed Tumor Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants Who Experience Grade 3/4 Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: miR200 levels (fold change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Identification and evaluation of cardiac arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency and spectra of the vibrating acupuncture needle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and spectra of tremor of the skin surrounding the acupunctured point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Virological Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Culture-confirmed IPD due to Pneumococcal Vaccine Serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Electrophysiological Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of treatment
Endpoint domain: Mortality/survival
Primary endpoint: duration of treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: number of treatment intake per day
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Determination of N2/N3 mediastinal lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Edmonton Symptom Assessment System (ESAS) Total Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in self-reported average pain score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Plaque scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of vaccine-related adverse events (AEs), graded by severity
Endpoint domain: Adverse events/effects
Primary endpoint: Measurement of neutralizing antibody titers to DEN1, DEN2, DEN3, and DEN4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Determination of seropositivity after second dose of vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Self-Care of Heart Failure Index (SCHFI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total Pain Reduction (Mouth and Throat)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of FFRCT-angio in evaluating coronary stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Non B type tympanogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ear outcomes
Primary endpoint: Knowledge of medication name
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Confidence in ability to raise the issue about weight
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Level of agreement in statements related to behaviour change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Confidence in initiating conversation about overweight
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Confidence in initiating conversation about underweight
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of rehospitalizations due to acute heart failure
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of deaths due to heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Bronchitis Severity Score (BSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: SUM8 (Daily Cough and Phlegm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Linkage to adult care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to Transplant
Endpoint domain: Mortality/survival
Primary endpoint: Cost of treating prostate-related events
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Overall Response Rates (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Serum Trimethylamine N-oxide (TMAO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with severe adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with protective levels of antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of CC with a depth higher than 50mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PARDI severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Related drug adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Bone metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Development of persistent confirmed multiple beta-cell autoantibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Improvement in Uncorrected Near Vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of acute myocardial injury and infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: T1 relaxation times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Treatment-related Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Infusion-Associated Reactions to VAL-1221
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with Anti-VAL-1221 Antibodies
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with GAA Antibodies
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of the ESSDAI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nebulizer solution output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIH-Stroke Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Normalised Forced Expiratory Volume in One Second (FEV1) AUC 0-12 hr
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pin Track Infection Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax for ALZ-801, tramiprosate, and NRM5074
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax for ALZ-801, tramiprosate, and NRM5074
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC for ALZ-801, tramiprosate, and NRM5074
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caries experience (DMFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Sleep architecture
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: change in cytokine levels in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change in CRP level in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in leucocyte level in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence and severity of nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of post cesarean section surgical site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Oxidative Stress Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of viral pneumonia caused by COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Patient receipt of ≥2 UDT
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: % of patients who have ≥1 early refill
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Physician satisfaction managing HIV-infected patients on COT for pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Occurrence of anastomotic leakage
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of cerebral deoxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Range of cerebral deoxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Blood Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Evaluated for Imaging Feasibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-transplant survival
Endpoint domain: Mortality/survival
Primary endpoint: Incidents of treatment related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Development of dnDSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the Lacosamide plasma concentration time curve from 0 to the last quantifiable data point (AUC(0-tz))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measured maximal concentration (Cmax) of Lacosamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the Lacosamide plasma concentration-time curve from 0 to the last quantifiable data point (AUC (0-tz)), normalized by body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measured maximal concentration (Cmax, norm) of Lacosamide normalized by body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Prostate Symptom Score (IPSS) Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Prostate Symptom Score (IPSS) Quality of Life (QoL) Question Change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: BPH Impact Index Change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Relative change in LCI2.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Blood Oxygen-Level Dependent (BOLD) signal change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Copeptin value (pmol/l)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of body weight lost
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bones volume assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soft tissue volume assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative positions of bones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal EtCO2 to predict poisoning complication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ganglion cell thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Abnormalities of physical findings and laboratory tests
Endpoint domain: Adverse events/effects
Primary endpoint: CNS treatment-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Area Under the Concentration-time Curve From 0 to 12 Hours (AUC12h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From 0 to Time to Last Quantifiable Concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular pressure curves
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Noncompartmental Pharmacokinetic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Two dimensional left ventricular ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Three dimensional left ventricular ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in AUC0-12h of FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: COPD prevalence
Endpoint domain: Mortality/survival
Primary endpoint: Excretion of radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma pazopanib clearance (CL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-t), AUC(0-8), Cmax and half-life (t1/2) of pazopanib and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical course duration of severe NTS enterocolitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: excretion of Salmonella in feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Hematological toxicity (grade ≥ 3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Yale-Brown Compulsive-Obsessive Scale Shopping Version
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Muscle activity on/off times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Root-mean-square (RMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: F2-isoprostanes/Cr
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Myeloperoxidase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Apical anatomical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior vaginal wall anatomical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in PFDI-20 scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With MA RSV LRTI Through 150 Days Post Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: LL growth difference between treatment groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CPR Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone specific alkaline phosphatase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: N-telopeptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pyridinoline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Deoxypyridinoline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: treatment retention status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: proportion of subjects achieving virologic suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: MS relapse recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Volume Transfer Rate (Ktrans)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Fahn-Tolosa-Marin Tremor Rating Scale - total score difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of GERD patients with an EE diagnosis confirmed by physician judgment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: effectiveness of astigmatism correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant's individual score in executive functions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time in glucose range 70-180
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inhibition of Grm1 signaling cascade components
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Prognosis Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: p-undercarboxylated osteocalcin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of adverse events (local and systemic post-vaccination reactions)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse events (systemic post-vaccination reactions)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of any serious adverse events during the trial
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Laboratory Toxicities of Grade ≥ 3
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Antibodies to Denosumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: whole body short-chain fatty acid metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peripapillary capillary perfusion density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-oriented combined endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional endpoint
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Insulin growth factor-1 (IGF-1) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Insulin growth factor binding proteins (IGFBP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in diurnal cortisol profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in structural MRI measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in emotional regulation and generation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Evaluation of liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Evaluation of tissue injury or abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in scores on cognitive assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Compliance with Medical Opioid Use Reduction Protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Response at one year post stem cell transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estradiol AUC during menstrual period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Progesterone AUC during menstrual period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Screw Placement Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With Anti-Therapeutic Antibodies (ATA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to Normalization of Respiratory Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of patients who are hernia- and complication-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of graft failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of chronic graft vs. host disease (GVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Ipsilateral Regional Cerebral Oxygen Saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of major structural defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nonfatal or fatal recurrent ischemic cerebrovascular event
Endpoint domain: Mortality/survival
Primary endpoint: Mean change in the dyskinesias rating scale (DRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes